Instill Bio press release (NASDAQ: TIL): Q4 non-GAAP EPS of -$1.26 beats by $2.14.
As of December 31, 2023, Instil had a total of $175.0 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments, which consisted of $9.2 million in cash and cash equivalents, 1 $.5 million in restricted cash, $141.2 million in marketable cash. securities and $23.2 million in long-term investments, compared to $260.9 million in total cash, cash equivalents and marketable securities, which consisted of $43.7 million in cash and cash equivalents and $217.2 million in marketable securities, as of December 31, 2022. Instil expects that its cash, cash equivalents, marketable securities and long-term investments as of December 31, 2023 will allow it to fund its operating plan beyond 2026.